GLP-1 Frenzy Continues: Eli Lilly Hits Record High, Q2 Expected to Shine, JPMorgan Targets $1,400, Multiple Brokers Raise Price Targets

Eli Lilly (LLY-US) stock hit a new historical high on July 8, primarily driven by JPMorgan (JPM-US) significantly raising its price target, multiple Wall Street investment banks recently expressing optimism about the company's outlook, and the continued strong growth momentum of its GLP-1 weight-loss drug pipeline, prompting investors to increase their positions.

JPMorgan analyst Chris Schott released a new research report after market close on July 7, raising Eli Lilly's price target from $1,300 to $1,400 while maintaining an 'Overweight' rating. The new target not only exceeds the average market target of approximately $1,243 but also implies about 17% upside from the closing price on July 6.

Schott highlighted that the key reasons for his bullish stance include Mounjaro's continued expansion in global market penetration, steady growth in U.S. demand for weight-loss medications, and the high growth potential still present in the company's core GLP-1 product line.

JPMorgan forecasts Eli Lilly's second-quarter revenue to reach $20.7 billion, approximately $300 million above the market consensus, with earnings per share (EPS) estimated at $8.85, $0.13 higher than the market consensus, reflecting the firm's optimistic outlook for the upcoming financial report.

In addition to JPMorgan, several other Wall Street firms have recently upgraded or reiterated their ratings on Eli Lilly.

Cantor Fitzgerald raised its price target from $1,230 to $1,350 on July 6, maintaining an 'Overweight' rating; RBC Capital Markets reiterated its 'Outperform' rating with a $1,250 price target; and Leerink Partners had previously raised its target to $1,232.

Cantor Fitzgerald noted that large biotech and pharmaceutical companies are expected to deliver better-than-expected overall performance in Q2, potentially leading multiple firms to raise their full-year revenue guidance.

Analysts broadly agree that Eli Lilly's primary growth driver remains its GLP-1 product line.

In particular, demand for the weight-loss drug Zepbound in the U.S. market continues to be robust, while the diabetes drug Mounjaro expands internationally. Additionally, next-generation products such as the oral GLP-1 candidate orforglipron (brand name Foundayo) and the triple receptor agonist retatrutide continue to boost market expectations for Eli Lilly's growth over the coming years.

Beyond product-line positives, Eli Lilly has recently received several favorable developments.

The U.S. launched the GLP-1 Bridge Program on July 1, allowing eligible insurance beneficiaries to purchase Zepbound and Foundayo with a monthly out-of-pocket cost of only $50, which the market expects will further expand the user base and market penetration of weight-loss medications.

Meanwhile, Eli Lilly's blood cancer drug Jaypirca recently received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending approval for treating chronic lymphocytic leukemia (CLL), paving the way for formal EU market authorization.

Additionally, recent U.S. market capital flows have shown sector rotation, with some funds shifting from chip and other tech stocks to healthcare equities. As one of the world's largest pharmaceutical companies by market capitalization, Eli Lilly has become a focal point for investor capital.

Fundamentally, Eli Lilly's stock has risen approximately 54% to 58% over the past year, surpassing a $1.1 trillion market cap. The company's year-over-year revenue growth reached 47%, its PEG (price/earnings-to-growth) ratio is around 0.33, and its Piotroski Score reached a perfect 9, reflecting strong profitability, financial health, and operational efficiency.

Market attention now turns to Eli Lilly's Q2 earnings report in August, watching whether the company can achieve the market-expected $20.7 billion in revenue and $8.85 in EPS, further validating whether the GLP-1 product line maintains high-speed growth and supports continued record highs in share price.